BioMarin Pharmaceutical (FRA:BM8) Cyclically Adjusted PS Ratio: (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:BM8 BioMarin Pharmaceutical Inc FRA:BM8
79 GF Score
Price €56.70
GF Value €77.10
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is BioMarin Pharmaceutical Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


BioMarin Pharmaceutical  (FRA:BM8) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


BioMarin Pharmaceutical Cyclically Adjusted PS Ratio Related Terms


BioMarin Pharmaceutical Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for BioMarin Pharmaceutical's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioMarin Pharmaceutical Cyclically Adjusted PS Ratio Chart

BioMarin Pharmaceutical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.78 12.33 9.97 6.49 4.65

BioMarin Pharmaceutical Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.52 4.26 4.63 4.23 4.33

FRA:BM8 vs MDGL, CORT, ARWR: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, BioMarin Pharmaceutical's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioMarin Pharmaceutical Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioMarin Pharmaceutical's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where BioMarin Pharmaceutical's Cyclically Adjusted PS Ratio falls into.


FRA:BM8
79GF Score
BioMarin Pharmaceutical Inc FRA:BM8
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioMarin Pharmaceutical Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

BioMarin Pharmaceutical's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, BioMarin Pharmaceutical's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=4.407/333.9520*333.9520
=4.407

Current CPI (Jun. 2026) = 333.9520.

BioMarin Pharmaceutical Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 1.488 241.428 2.058
201612 1.616 241.432 2.235
201703 1.631 243.801 2.234
201706 1.648 244.955 2.247
201709 1.649 246.819 2.231
201712 1.760 246.524 2.384
201803 1.760 249.554 2.355
201806 1.789 251.989 2.371
201809 1.873 252.439 2.478
201812 1.736 251.233 2.308
201903 1.976 254.202 2.596
201906 1.906 256.143 2.485
201909 2.201 256.759 2.863
201912 2.218 256.974 2.882
202003 2.404 258.115 3.110
202006 2.116 257.797 2.741
202009 2.053 260.280 2.634
202012 2.052 260.474 2.631
202103 2.201 264.877 2.775
202106 2.258 271.696 2.775
202109 1.891 274.310 2.302
202112 2.119 278.802 2.538
202203 2.350 287.504 2.730
202206 2.642 296.311 2.978
202209 2.621 296.808 2.949
202212 2.720 296.797 3.061
202303 2.843 301.836 3.146
202306 2.802 305.109 3.067
202309 2.817 307.789 3.056
202312 3.132 306.746 3.410
202403 3.005 312.332 3.213
202406 3.283 314.175 3.490
202409 3.428 315.301 3.631
202412 3.521 315.605 3.726
202503 3.543 319.799 3.700
202506 3.704 322.561 3.835
202509 3.506 324.800 3.605
202512 4.000 324.054 4.122
202603 3.367 330.213 3.405
202606 4.407 333.952 4.407

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is BioMarin Pharmaceutical (FRA:BM8) Overvalued in 2026?

Based on GuruFocus' analysis, BioMarin Pharmaceutical stock appears to be undervalued. The current stock price of €56.70 is trading 26.5% below its estimated GF Value™ of €77.10. GuruFocus considers BioMarin Pharmaceutical to be Modestly Undervalued.

Key valuation signals for FRA:BM8:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €77.10 vs. price of €56.70 (26.5% below fair value)
  • GF Score™: 79/100 with 5 warning signs

No single metric tells the full story. See the FRA:BM8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioMarin Pharmaceutical Business Description

Address 770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
79GF Score

Get the complete analysis for FRA:BM8

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€56.70
Price
€77.10
GF Value